Conceptio › Archive › HAL (France)
HAL (France)open access

Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND

Andrew Blauvelt et al.
HAL (France) · Papers · License: Open Access
Open Source ↗
atopic-dermatitisefficacylong-term
0, ECZTEND, Efficacy, Open-label, 1, Long-term, IL-13, Atopic dermatitis
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 144942
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.